



INVESTOR FORUM

October 17-18, 2018
The Westin • St. Francis, San Francisco, CA



Accelerate Discovery. Amplify Returns.

The **BIO Investor Forum** is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2019.

BIO Investor Forum features include:

- Public and venture-stage company presentations.
- Expert-led workshops on the latest market and investment opportunities with emphasis on drug and technology development.
- BIO One-on-One Partnering™ meetings.
- Premier opportunity to network with industry executives and investors focused exclusively on life sciences.

Target Audience

- Private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences.

Why Investors Attend

- **Hear** from and meet with executives at the top life sciences growth companies.
- **Evaluate** fresh investment opportunities including compatible, complementary and competitive companies.
- **Benefit** from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
- **Get a ‘big picture’ overview** of the industry and the issues affecting product innovation, capitalization, and commercialization.

Why Companies Attend

- **Meet** one-on-one with new and current investors, analysts, and partnering companies.
- **Get the pulse** on the latest life sciences investment trends from sophisticated investment and company executives.
- **Showcase** your company story in presentations to qualified investors.
- **Network** with peers, investors and potential partners.



860
Attendees



168
Presenting
Companies



2,760
Partnering
Meetings Scheduled



369
Partnering
Companies

27% INCREASE
OVER 2016


7% INCREASE
OVER 2016

#BIF18

bio.org/investorforum


AUDIENCE DEMOGRAPHICS

COMPANIES BY TYPE




- Biopharma
- Investor
- Other

COMPANIES BY NUMBER OF EMPLOYEES



- <50 Employees
- 51 to 1,000 Employees
- 1,000* Employees

COMPANIES BY REGION



- USA
- Other
- Asia
- Europe

WHAT ATTENDEES ARE SAYING

Like being at JPM without the crowds.


Excellent forum for meeting investors or alliance partners for biotech deals.

Good keynotes, receptions and management teams.

Lots of opportunities to meet investors.

The investors were great. I don't know what similar access I'll have to such a collection again.

ATTENDEES BY JOB TITLE



- C-level
- Executive/VP
- Director
- Other
- Investor

2017 BIO INVESTOR FORUM Advisory Committee



Mahima Agochiya, PhD
Business Development &
Program Manager, SPARK
Translational Research
Program, School of Medicine,
Stanford University



James Antonopoulos
Managing Director and
Co-Head of Healthcare
Investment Banking,
ROTH Capital Partners



Scott C. Brun, MD
Vice President, Corporate
Strategy Office Head,
AbbVie Ventures



Rajeev Dadoo, PhD
Partner, S.R. One, Limited



David H. Donabedian, PhD
Venture Partner,
Longwood Fund



Patrick Enright
Managing Director,
Longitude Capital



Tao Huang, PhD, JD
Venture Partner,
Internal Legal and
IP Counsel



Charlotte Hubbert, PhD
Program Investment
Officer, Gates Foundation
Venture Capital



Jan Hughes
Director,
Business Development,
BioPacific Investors



Jennifer Landress
Senior Vice President and
Chief Operating Officer,
Biocom



John Miller
Chief Executive Officer,
Tourette Association
of America



Tim Noblitt
Consultant, Corporate
Business Development,
Eli Lilly and Company



Julia C. Owens, PhD
President and Chief
Executive Officer,
Millendo Therapeutics



Sara Radcliffe
President and Chief Executive
Officer, California Life Science
Association (CLSA)



Wendy Robbins, MD
President
& Chief Executive Officer,
Blade Therapeutics



Matthew Roden, PhD
Vice President and Head
of Strategic Corporate
Development,
Bristol-Myers Squibb



Lynn Seely, MD
President and
Chief Executive Officer,
Myovant Sciences



Asish K. Xavier, PhD
Vice President, Venture
Investments, Johnson &
Johnson Innovation -
JJDC, Inc.